Polypeptide With Localisation/Targeting Motif TRIZ Cases

ActRIIA:TβRII heteromultimers antagonize multiple Smad 2/3 activating ligands while maintaining selectivity against BMP10.

Dual CARs aggregate on distinct ligand epitopes to activate T-cells, eliminating off-tumor toxicity from soluble antigen recognition.

Engineering chimeric negative-strand RNA viruses with fusion proteins expressing foreign ectodomains reduces host resistance and vaccination costs.

Engineered NKG2C receptors boost natural killer cell cytotoxicity against cancer cells by increasing binding affinity for HLA-E complexes.

Diagnostic fusion protein reagents detect SARS-CoV-2 antibodies via hemagglutination, bypassing complex laboratory equipment and reducing turnaround time.

A CD19 chimeric antigen receptor uses a 4g7 single-chain variable fragment to target malignant cells.

Photo-specific binding proteins load cargo proteins into exosomes, resolving yield and toxicity trade-offs in therapeutic delivery.

Multispecific IL-15 fusion proteins link CD3 binding domains to interleukin-15 polypeptides for targeted immune activation.

Segmented CAR T cells target tumor antigens while utilizing B cell markers to resolve the trade-off between targeting capability and long-term maintenance.

Bispecific CAR-T cells using a humanized CD19 antibody reduce antigen escape risks and improve tumor elimination efficacy.

Engineered chimeric antigen receptors with optimized variable regions bind BCMA on cancer cells to enhance targeted killing.

Chimeric intracellular signaling molecules reprogram T cell metabolism to overcome hypoxia resistance in tumor microenvironments.

C-terminal GLP-1 peptides inhibit fatty acid oxidation via fatty acid binding protein delivery, treating obesity in insulin-resistant states.

Modified nucleic acids encoding human insulin and glucokinase enable host cells to produce therapeutic proteins autonomously.

Engineered antigen binding proteins target PRAME peptide-MHC complexes, overcoming low native TCR affinity to reduce off-target toxicity.

Novel bacterial expression vector combines signal peptides with truncated yebF carrier to enhance recombinant protein secretion.

A secretion fusion partner directs recombinant proteins through the secretory pathway, resolving low secretion yields and complex purification steps.

Chimeric Tim4 receptors integrate CD3ζ, CD28, and TLR domains to sustain T cell function and reduce exhaustion during tumor targeting.

Genetically encoded probes incorporate 2-furancarbonyl lysine via pyrrolysyl-tRNA synthetase to resolve intracellular stability and localization trade-offs.

Bispecific molecules targeting ZNRF3 and LGR4 receptors stabilize Wnt signaling pathways in liver tissue.

Truncating membrane domains and adding disulfide bonds stabilizes HCMV gB trimers, overcoming purification failures in vaccine design.

Standardized transit peptide sequences ensure efficient protein processing and reliable herbicide tolerance by eliminating variable localization outcomes.

Lym-1 and Lym-2 chimeric antigen receptors target HLA-DR antigens on tumor cells to deliver potent cytotoxic signals.

CRISPR-Cas9 deletes CD33 exon 2 in donor stem cells, allowing selective cancer killing while sparing normal tissue.

Peptidic antigen switches bridge CAR receptors and tumor targets, reducing off-target cytotoxicity while allowing periodic dose control.

Engineered chimeric antigen receptors with 4-1BB co-stimulatory domains redirect T-cell reactivity toward GD3-positive tumor cells.

Modified antibody structures target unique HER2 epitopes, overcoming trastuzumab resistance and enabling synergistic therapy for breast and gastric cancers.

Chimeric antigen receptors targeting MUC1 and K-ras overcome immune evasion in pancreatic cancer.

Recombinant DNA molecules encode fusion proteins that modulate alpha-synuclein expression, addressing the unmet need to halt Parkinson's disease progression.

A peptide decoy antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 to reduce immunostimulation.

Chimeric immunogen generates antibodies that lyse mIgA-expressing B lymphocytes and reduce IgA production.

A CDH26-Fc fusion protein modulates leukocyte migration and suppresses T cell activation through cadherin-mediated interactions.

A synthetic peptide derived from amyloid precursor protein sequences induces pluripotent stem cell differentiation into endodermal lineages.

Magneto fusion proteins resolve poor light penetration in dense tissues by enabling non-invasive magnetic control of deep brain regions.

Bacterial phytochrome mediates far-red light activation of receptor tyrosine kinases, eliminating invasive fiber implantation for deep-tissue stimulation.

Targeting tau amino acids 15-24 enables a humanized antibody to cross the blood-brain barrier and lower pathological aggregation.

SOCS3 fusion proteins inhibit pathological angiogenesis by modulating inflammatory cytokine signaling pathways within the tumor microenvironment.

ASGPR antibodies bind liver receptors to transport interferon payloads, reducing systemic side effects while enhancing antiviral activity.

A VEGF-binding peptide delivers therapeutic agents directly into tumor cells via selective translocation.

A prion-Fc fusion protein binds neurotoxic aggregates and induces phagocytic clearance via Fc-mediated recycling.

Chimeric receptors targeting MUC16 reduce tumor burden while minimizing toxicity through segmented domain design.

An H5 avian influenza vaccine strain incorporates an influenza B neuraminidase protein as a differentiation marker.

Replacing endogenous mouse CD40 with the human gene resolves the contradiction between experimental simplicity and accurate disease state reflection.

Antibodies targeting Foxp3 peptides on MHC molecules selectively deplete regulatory T cells without harming effector T cells.

Peptides targeting M1, M3, and M5 motifs reduce neuronal toxicity and mitochondrial dysfunction in ALS and FTD models.

Recombinant adeno-associated virus delivers SARS-CoV-2 antigen polypeptides to induce neutralizing antibodies.

Recombinant ovomucoid and ovalbumin proteins replace animal sources to sustainably replicate egg white foam properties.

Segmented expression cassette with modified signal peptide overcomes suboptimal secretion efficiency in Bifidobacterium.

Stem domain polypeptides present conserved epitopes to elicit robust immune responses against diverse influenza strains.

Selective membrane translocation separates biological molecules from impurities during synthesis, reducing purification complexity and production time.